BioNTech is trading 18% up now at $109.47 after positive Phase 3 melanoma-vaccine results from Moderna and Merck lifted mRNA and biotech sentiment.
- Sector catalyst appears primary; vaccine developers gained broadly, with the move substantially stronger than the 3.73% sector advance.
- New Arbutus and Genevant patent litigation over Comirnaty creates company-specific risk, not today’s gain.
- Move indicates heightened trading interest and possible BioNTech oncology-pipeline optimism; no fresh BioNTech clinical or earnings announcement was identified.